213684-80-1

Basic information

• Product Name: methyl 2-((6-((2,6-diisopropylphenyl)amino)-6-oxohexyl)thio)benzo[d]oxazole-4-carboxylate
• Synonyms: methyl 2-((6-((2,6-diisopropylphenyl)amino)-6-oxohexyl)thio)benzo[d]oxazole-4-carboxylate
• CAS NO: 213684-80-1
• Molecular Weight: 482.644
• Mol File: 213684-80-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 2-((6-((2,6-diisopropylphenyl)amino)-6-oxohexyl)thio)benzo[d]oxazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-((6-((2,6-diisopropylphenyl)amino)-6-oxohexyl)thio)benzo[d]oxazole-4-carboxylate(213684-80-1)
• EPA Substance Registry System: methyl 2-((6-((2,6-diisopropylphenyl)amino)-6-oxohexyl)thio)benzo[d]oxazole-4-carboxylate(213684-80-1)

Safety Data

• Hazardous Substances Data: 213684-80-1(Hazardous Substances Data)

Upstream product

• 288-42-6 oxazol 
• 199592-72-8 6-bromo-N-(2,6-diisopropylphenyl)hexanamide 
• 24544-04-5 2,6-diisopropylbenzenamine 
• 17672-21-8 2-amino-3-hydroxy-benzoic acid methyl ester 
• 548-93-6 3-hydroxyanthranilic acid 
• 4224-70-8 6-bromohexanoic acid 

Downstream Products

• 213684-81-2 2-((6-((2,6-diisopropylphenyl)amino)-6-oxohexyl)thio)benzo[d]oxazole-4-carboxylic acid 
• 213684-82-3 N-(2,6-diisopropylphenyl)-6-((4-(hydroxymethyl)benzo[d]oxazol-2-yl)thio)hexanamide 
• 213684-83-4 N-(2,6-diisopropylphenyl)-6-((4-((N,N-dimethylamino)methyl)benzo[d]oxazol-2-yl)thio)hexanamide 

Relevant articles and documents

Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors

We describe our molecular design of aortic-selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT, also abbreviated as SOAT) inhibitors, their structure–activity relationships (SARs) and their pharmacokinetic (PK) and pharmacological profiles. The connection of two weak ligands—N-(2,6-diisopropylphenyl)acetamide (50% inhibitory concentration [IC50] = 8.6 μM) and 2-(methylthio)benzo[d]oxazole (IC50 = 31 μM)—via a linker comprising a 6 methylene group chains yielded a highly potent molecule, 9-(benzo[d]oxazol-2-ylthio)-N-(2,6-diisopropylphenyl)nonanamide (3h) that exhibited high potency (IC50 = 0.004 μM) toward aortic ACAT. This head-to-tail design made it possible to markedly enhance the activity to 2150- to 7750-fold and to discriminate the isoform-selectivity based on the double-induced fit mechanism. At doses of 1 and 3 mg/kg, 3h significantly decreased the lipid-accumulation areas in the aortic arch to 74 and 69%, respectively without reducing the plasma total cholesterol level in high fat- and cholesterol-fed F1B hamsters. Here, we demonstrate the antiatherosclerotic effect of 3h in vivo via its direct action on aortic ACAT and its powerful modulator of cholesterol level. This molecule is a potential therapeutic agent for the treatment of diseases involving ACAT-1 overexpression.